SARS-CoV-2 Variant Pseudoviruses for Neutralization Assays

 Product Offerings   |  Workflow   | Reproducible & Specific Results   |  Breadth of Neutralization Data   |  FDA Guidance   |  Case Study   | Contact Us   |  FAQs

As SARS-CoV-2 Continues to Evolve, We've Got the Latest Variants

Advantages over live SARS-CoV-2 virus

✔Safe in BSL-2

✔Ready-to-use particles and kits

✔Convenient reporter, compatible with standard equipment

✔Quality controlled production for use as a critical reagent

Common Applications

✔Antibody neutralization

✔Serum screening

✔High-throughput assays

SARS-CoV-2 Pseudovirus Product Offerings

SARS-CoV-2 Pseudovirus Neutralization Assay Workflow

Whether you’re running a single microneutralization assay or conducting high-throughput screening, SARS-CoV-2 RVPs adapt to your workflow.

Protocol Overview

• Prepare target cells (293T-hsACE2 or your preferred line)
• Pre-incubate RVPs with test antibody or serum
• Infect cells with neutralization mixture (typically 1 hour)
• Incubate to allow reporter expression (48-72 hours)
• Read signal by flow cytometry or high-content imager (GFP), or luminometer (luminescence)
• Calculate metrics (NT₅₀, IC₅₀, neutralization titer)

Assay Formats We Support

• 96-well and 384-well plate formats
• GFP or luciferase reporter readouts
• Serum panels or antibody libraries

Want a faster, simpler workflow? Our new Ready Reporter Virus kits offer the fastest path to the same results. Built on the same technology as RVPs, RRV kits offer thaw-and-use convenience with same-day results—no cell culture required.

Reproducible, Specific SARS-CoV-2 Neutralization Data

Reporter Virus Particles (RVPs) provide highly reproducible and specific neutralization data to support your research.

Our ISO 9001-certified quality management system means you can count on reliable reagents that perform as expected in your lab. As the neutralization curves show (below left), there is minimal variation in neutralization data across RVP production lots. These six assays were run by different operators on different lots of RVPs over two years, resulting in a very consistent NT50 for the same antibody over time. Our careful attention to RVP production and critical quality attributes means you can focus on your research.

With SARS-CoV-2 RVPs, you can verify the specificity of your antibody and assess its ability to block infection. Results from a neutralization assay (below right) show that RVPs faithfully present spike protein. Here, benchmark SARS-CoV-2 antibody VHH-72 specifically blocks infection by the expected SARS-CoV-2 RVPs, and not a mismatched control RVP. Moreover, as the concentration of the neutralizing antibody (orange-line) increases along the x-axis, you see a neutralization curve from which it is possible to determine the neutralizing titer, or NT50.

(Left) Neutralization assay across 6 production lots of SARS-CoV-2 (D614G) RVPs show high lot-to-lot consistency in neutralization. (Right) SARS-CoV-2 RVPs are specifically neutralized by SARS-CoV-2–directed antibody VHH-72.

SARS-CoV-2 Variant Pseudoviruses Can Reveal An Antibody’s Breadth of Neutralization

For more about neutralization assays, including tips
for developing your own assay, visit Pseudovirus
Neutralization Assays: A how-to guide for getting started. 

Integral Molecular’s broad catalog of SARS-CoV-2 variant pseudoviruses makes it easy to evaluate your antibody’s neutralization capability across ancestral and emerging variants.

SARS-CoV-2 Pseudoviruses Support FDA Guidance

Our rapid development of SARS-CoV-2 variant pseudoviruses gives researchers on-demand access to new strains as they emerge.

Monoclonal antibodies can provide efficacious therapy for COVID-19 treatment, but rapid mutation often leads to viral escape. Immunome developed a SARS-CoV-2 three-antibody cocktail with broad neutralization potency. They needed to test their antibody cocktail against a large panel of viral variants of concern.

Read the Case Study